Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma

References

• Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert Rev Respir Med. 2016;10(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22.
   PubMed Web of Science ®Google Scholar
• Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis. 2008;2:163–171.
   PubMedGoogle Scholar
• Shrimanker R, Pavord ID. Interleukin-5 inhibitors for severe asthma: rationale and future outlook. BioDrugs. 2017;31(2):93–103.
   PubMed Web of Science ®Google Scholar
• Chung KF. Clinical management of severe therapy-resistant asthma. Expert Rev Respir Med. 2017;11(5):395–402.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. COUNTERPOINT: will new anti-eosinophilic drugs be useful in asthma management? no. Chest. 2017;151(1):17–20.
   PubMed Web of Science ®Google Scholar
• Ghazi A, Trikha A, Calhoun WJ. Benralizumab - a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113–118.
   PubMed Web of Science ®Google Scholar
• Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1–2):17–27.
   PubMedGoogle Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.e2.
   PubMed Web of Science ®Google Scholar
• Ishino T, Pasut G, Scibek J, et al. Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. J Biol Chem. 2004;279(10):9547–9556.
   PubMed Web of Science ®Google Scholar
• Tan LD, Bratt JM, Godor D, et al. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71–81.
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125(6):1237–1244. DOI:10.1016/j.jaci.2010.04.005.
   PubMed Web of Science ®Google Scholar
• Jin F, White W, Gossage D, et al. Multiple ascending subcutaneous (SC) dose study of MEDI-563: pharmacokinetics and immune response in adult asthmatics [abstract]. European Respiratory Society – 20th Annual Congress, Barcelona, Sept 18-22, 2010, P4553
   Google Scholar
• Gossage D, Geba G, Gillen A, et al. A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL5Ra monoclonal antibody, in adult asthmatics [abstract]. European Respiratory Society – 20th Annual Congress, Barcelona, Sept 18-22, 2010, P1177
   Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086–1096.
   PubMed Web of Science ®Google Scholar
• Pham T, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29.
   PubMed Web of Science ®Google Scholar
• Saito H, Yuji W, Kawai H, et al. Ascending single intravenous and subcutaneous dose studies of benralizumab in Japanese healthy male volunteers: safety, tolerability, pharmacokinetics and pharmacodynamics [abstract]. Am J Respir Crit Care Med. 2015;191:A4270.
   Web of Science ®Google Scholar
• Wang B, Yan L, Yao Z, et al. Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma. PT Pharmacometrics Syst Pharmacol. 2017;6(4):249–257. DOI:10.1002/psp4.12160.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–659.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890. DOI:10.1016/S2213-2600(14)70201-2.
   PubMed Web of Science ®Google Scholar
• Wang B, Yan L, Hutmaker M, et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma [abstract]. Am J Respir Crit Care Med. 2014;189:A1324.
   Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20. DOI:10.1016/j.ajem.2014.09.036.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. DOI:10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. DOI:10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568–576.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Mansur AH, Jacobs JS, et al. Functionality, reliability, and performance of an accessorized pre-filled syringe with home-administered subcutaneous benralizumab for adult patients with severe asthma [abstract]. Am J Respir Crit Care Med. 2017;195:A3194.
   Web of Science ®Google Scholar
• Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017;37(2):397–412.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Caminati M, et al. Targeting interleukin-5 or interleukin-5Ra: safety considerations. Drug Saf. 2017;40:559–570.
   PubMed Web of Science ®Google Scholar
• Low K, Bardin PG. Targeted therapy for severe asthma: identifying the right patients. Mol Diagn Ther. 2017;21(3):235–247.
   PubMed Web of Science ®Google Scholar
• Nixon J, Newbold P, Mustelin T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57–77.
   PubMed Web of Science ®Google Scholar
• Newbold P, Wu Y, Shih V, et al. High blood eosinophil concentrations and serum biomarkers of low IL-13 pathway activation at baseline predict exacerbation rate reduction by benralizumab for patients with moderate to severe asthma [abstract]. Am J Respir Crit Care Med. 2016;193:A4351.
   Web of Science ®Google Scholar
• Wang FP, Liu T, Lan Z, et al. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166833.
   PubMed Web of Science ®Google Scholar
• Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138.
   PubMed Web of Science ®Google Scholar